Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
PZ HTL SA
GLOBETECH PUBLISHING

Bayer Acquires Herbal Medicine Maker Steigerwald

By BiotechDaily International staff writers
Posted on 27 May 2013
Pharmaceutical giant Bayer AG (Leverkusen, Germany) has agreed to buy privately held Steigerwald Arzneimittelwerk (Darmstadt, Germany), a maker of herbal treatments.

The acquisition is seen as a strategic move by Bayer to strengthen its consumer care business. Steigerwald’s product portfolio includes Iberogast for the treatment of functional gastrointestinal disorders and Laif for the treatment of mild to moderate depression, among others. Financial details of the transaction were not disclosed, but Bayer has made known that Steigerwald had generated sales of 61.3 million Euros in 2012. The transaction is subject to fulfillment of the usual conditions, including antitrust clearance, and is expected to close at the beginning of July 2013.

“This transaction is further evidence of our commitment to augment organic growth with strategic bolt-on acquisitions. It will allow us to provide consumers with an even broader range of self-care options,” said Marijn Dekkers, CEO of Bayer AG. “This acquisition broadens our product offering for the treatment of gastrointestinal disorders and gives us the opportunity to enhance our presence in Germany, the fast-growing regions of East-Central Europe, and the CIS countries.”

“As a family-owned business, we take great pride in what we have achieved in nurturing and developing our brands,” said Klaus Möller, one of Steigerwald’s shareholders. “We believe that Bayer, with its extensive marketing, sales, distribution, and research expertise, is well positioned to take our success to the next level.”

Iberogast is a proprietary liquid blend of nine herbs, including bitter candytuft, angelica root, milk thistle fruit, celandine herb, caraway fruit, liquorice root, peppermint herb, balm leaf, and chamomile flower. It is named after the genus (Iberis) of one of its ingredients, it is also claimed to possess anti-inflammatory, antioxidative, and free radical-inhibiting properties as well as reducing gastric acid secretion.

Laif is based on St John's wort, widely known as an herbal treatment for depression, probably due to its inhibition of reuptake of neurotransmitters such as serotonin (5 HT), similar to conventional selective serotonin reuptake inhibitor (SSRI) antidepressant drugs. The major active antidepressive constituents in St John's wort are thought to be hyperforin and hypericin, although other biologically active constituents present, for example, flavonoids and tannins, may also be involved.

Related Links:

Bayer AG
Steigerwald Arzneimittelwerk



Channels

Genomics/Proteomics

view channel
Image: Biopsy of small bowel showing celiac disease manifested by blunting of villi, crypt hyperplasia, and lymphocyte infiltration of crypts (Photo courtesy of Wikimedia Commons).

Reduced Elafin Levels Associated with Celiac Disease Bowel Inflammation

Levels of the enzyme elafin, an endogenous serine protease inhibitor, were lower in the small intestinal epithelium of patients with active celiac disease (CD) as compared to similar tissue from control patients.... Read more

Drug Discovery

view channel

Retinoic Acid Prevents Precancerous Breast Cells from Progressing to Full-Blown Cancer

Retinoic acid, a derivative of vitamin A, was found to prevent pre-cancerous breast cells from progressing to full-blown cancer but did not have any effect on breast tumor cells. Investigators at Thomas Jefferson University (Philadelphia, PA, USA) worked with a novel breast cancer model that had been developed by treating... Read more

Biochemistry

view channel

Mitochondrial Cause of Aging Can Be Reversed

Researchers have found a cause of aging in lab animals that can be reversed, possibly providing an avenue for new treatments for age-related diseases including type 2 diabetes, cancer, muscle wasting, and inflammatory diseases. The researchers plan to begin human trials late 2014. The study, which was published December... Read more

Therapeutics

view channel

Cytokine Identified That Causes Mucositis in Cancer Therapy Patients

The action of the cytokine interleukin 1-beta (IL-1beta) has been found to underlie the onset of mucositis, a common, severe side effect of chemotherapy and irradiation of cancer patients. Mucositis occurs as a result of cell death in reaction to chemo- or radiotherapy. The mucosal lining of the mouth becomes thin, may... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.